As our work in women’s midlife health continues to evolve, so does our commitment to advancing the future of menopause research, education, and evidence-based care.
With a vision for a more dedicated initiative centered around scientific investigation, preventive healthcare, data-driven clinical insight, and women’s midlife wellness, the Americas Institute for Menopause (AIM) has been founded as the research and educational wing of Galleria Women’s Health.
AIM is focused on advancing research, education, and innovation in menopause and women’s healthy aging through longitudinal study, multidisciplinary collaboration, clinical education, and the dissemination of evidence to the wider scientific and healthcare community.
Our active research initiatives explore menopause-related hormonal, metabolic, physiologic, and lifestyle
factors that shape long-term women’s health and healthy aging.
MetaboLonge™ is a physician-led research program of the Americas Institute for Menopause (AIM), the research and educational wing of Galleria Women’s Health. The program focuses on visceral adiposity, cardiometabolic health, lifestyle medicine, and healthy aging in postmenopausal women.
Menopause, visceral adiposity, metabolic health, and healthy aging.
Physician-led Functional and Lifestyle Medicine research with a structured menopause-focused intervention.
1:1 randomized controlled trial with treatment and usual-care control arms.
Examines menopause-related hormonal changes and their relationship to long-term women’s health outcomes.
Focuses on how estrogen-related physiologic changes may influence metabolism, body composition, and cardiometabolic risk.
Investigates visceral fat, body composition, skeletal muscle, and related metabolic health markers.
Evaluates risk pathways related to insulin resistance, blood pressure, lipid markers, and metabolic dysfunction.
Studies the role of nutrition, physical activity, sleep, stress management, and preventive lifestyle strategies.
Explores cognitive screening, perceived stress, sleep quality, and emotional wellbeing in midlife and postmenopausal women.
Early implementation data indicate reductions in visceral adiposity among participants with complete visceral fat measurements.
MetaboLonge evaluates changes in metabolic and inflammatory risk markers, including HbA1c, HOMA-IR, lipid profile, blood pressure, and related cardiometabolic outcomes.
The program tracks body composition, including visceral fat, waist circumference, skeletal muscle mass, and related markers of metabolic and functional health.
Findings reflect early implementation observations and ongoing longitudinal evaluation. Full controlled outcome data will be assessed through the randomized study design and 36-month follow-up period.
A collection of scholarly perspectives, clinical commentary, public health discussions, and research abstracts focused on menopause, women’s midlife health, preventive care, and healthcare systems innovation.
An evidence-based manuscript examining menopause as an underrecognized public health issue and exploring the need for better integration of menopause care within healthcare systems, clinical education, surveillance frameworks, and preventive women’s healthcare.
An evidence-based manuscript examining menopause as an underrecognized public health issue and exploring the need for better integration of menopause care within healthcare systems, clinical education, surveillance frameworks, and preventive women’s healthcare.
An evidence-based manuscript examining menopause as an underrecognized public health issue and exploring the need for better integration of menopause care within healthcare systems, clinical education, surveillance frameworks, and preventive women’s healthcare.